#TLSA

StockTitan

@stocktitan.net

1 month ago

Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab Tiziana Life Sciences (Nasdaq: TLSA) announced peer-reviewed publication of an open-label study of intranasal foralumab in non-active secondary progressive multiple sclerosis (na-SPMS) in Neurology Neuroimmunology & Neuroinflammation on Jan 20, 2026. The 10-patient study reported no serious treatment-related adverse events, stabilization of EDSS in all patients with improvement in 3 of 4 treated 12 months, MFIS fatigue improvement in 6 of 10, no new T2 MRI lesions, reduced microglial activation by TSPO-PET (p<0.05), and single-cell RNA-seq showing increased Tregs and TGFβ. A randomized double-blind Phase 2 in na-SPMS is ongoing with top-line data expected in 1H 2026.

#TLSA Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab

www.stocktitan.net/news/TLSA/tiziana-life-s...

StockTitan

@stocktitan.net

1 month ago

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million Tiziana Life Sciences (Nasdaq: TLSA) priced a registered direct offering of 6,400,000 ordinary shares at $1.25 per share, expected to raise approximately $8.0 million in gross proceeds before expenses. Each share purchased includes a warrant to buy one ordinary share at $1.50 exercisable through July 16, 2026, potentially generating up to an additional $9.6 million. The Offering, conducted without an underwriter and expected to close on January 16, 2026, was led by CEO Ivor Elrifi and included a purchase by Executive Chairman Gabriele Cerrone. Proceeds are intended to fund completion of the company’s Phase 2 na-SPMS and MSA clinical trials and topline data readouts.

#TLSA Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million

www.stocktitan.net/news/TLSA/tiziana-life-s...

StockTitan

@stocktitan.net

2 months ago

Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a

#TLSA Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA

www.stocktitan.net/news/TLSA/tiziana-files-...

StockTitan

@stocktitan.net

2 months ago

Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman Tiziana Life Sciences (Nasdaq: TLSA) announced that Executive Chairman and Founder Gabriele Cerrone purchased 97,687 common shares on Dec. 19, 2025.After the purchase his total holding is 43,374,830 common shares, representing 36.08% of issued share capital.

#TLSA Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman

www.stocktitan.net/news/TLSA/tiziana-life-s...

Dave Stork

@davestork.nl

2 months ago

Azure DNS REST API Reference Learn how the Microsoft Azure DNS Resource Provider REST API allows you to create and modify DNS zones and records hosted within Azure.

Obviously, changing the #certificate requires changing this #TLSA record in order to prevent false positives. Idealy in an automated process, requiring an DNS provider API. If they don't have it , you might want to consider using #Azure #DNS and it's #API: learn.microsoft.com/en-us/rest/a...

Dave Stork

@davestork.nl

2 months ago

Azure DNS REST API Reference Learn how the Microsoft Azure DNS Resource Provider REST API allows you to create and modify DNS zones and records hosted within Azure.

Day 19 of #ITAdvent. One other consideration of using Automatic Certificate Management Environment or #ACME is that you also need to update your #TLSA #DNS record for #DANE. This record contains the #certificate thumbprint, binding that certificate and enabling clients to check URI authenticity.

StockTitan

@stocktitan.net

2 months ago

Tiziana Life Sciences to Ring the Closing Bell at Nasdaq Tiziana Life Sciences (Nasdaq: TLSA) announced that Executive Chairman and Founder Gabriele Cerrone will ring the Nasdaq Closing Bell in Times Square on December 17, 2025 from 3:45 PM to 4:15 PM ET. The ceremony celebrates the company's progress advancing intranasal foralumab, a fully human anti-CD3 monoclonal antibody delivered nasally to target neurodegenerative and inflammatory diseases including multiple sclerosis, Alzheimer's disease, and ALS.The company noted recent pipeline progress, including dosing the first patient in its Phase 2 Alzheimer's trial, and provided livestream links for the event.

#TLSA Tiziana Life Sciences to Ring the Closing Bell at Nasdaq

www.stocktitan.net/news/TLSA/tiziana-life-s...

StockTitan

@stocktitan.net

2 months ago

Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial Tiziana Life Sciences (Nasdaq: TLSA) announced that the first patient was dosed on December 17, 2025 in its randomized, placebo-controlled Phase 2 trial of intranasal foralumab for early Alzheimer’s disease.The trial will evaluate foralumab as monotherapy and combined with FDA-approved anti-amyloid therapies lecanemab (Leqembi) or donanemab, and is supported by TSPO-PET imaging data showing persistent microglial activation after amyloid reduction. The program tests an immunomodulatory approach targeting residual neuroinflammation with intranasal anti-CD3 foralumab; enrollment will continue and clinical outcomes are pending.

#TLSA Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial

www.stocktitan.net/news/TLSA/tiziana-life-s...

StockTitan

@stocktitan.net

3 months ago

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer Tiziana Life Sciences (Nasdaq: TLSA) announced on December 15, 2025 that its Chief Executive Officer, Ivor Elrifi, purchased 163,400 shares of Tiziana common stock in the open market.Following this transaction, the CEO's total purchased shares amount to 357,848. The purchase was executed on the open market and reflects an insider buy by the company's chief executive.

#TLSA Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

www.stocktitan.net/news/TLSA/tiziana-life-s...

StockTitan

@stocktitan.net

3 months ago

Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering Tiziana Life Sciences (Nasdaq: TLSA) announced on Dec 15, 2025 that it has withdrawn its proposed public offering of common shares. The company said the withdrawal was made due to market conditions. The release also states that it does not constitute an offer to sell or a solicitation to buy securities in any jurisdiction prior to required registration or qualification.

#TLSA Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering

www.stocktitan.net/news/TLSA/tiziana-life-s...

StockTitan

@stocktitan.net

3 months ago

Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial Tiziana Life Sciences (Nasdaq: TLSA) announced on Dec 12, 2025 that enrolment has begun in its Phase 2 randomized, placebo-controlled early Alzheimer’s trial and the company expects to dose the first patient next week. The study will test intranasal foralumab as monotherapy and combined with FDA-approved anti-amyloid therapies lecanemab or donanemab.Baseline cognitive testing, fluid biomarkers and TSPO-PET imaging were completed in initial participants; new TSPO-PET evidence showed persistent, widespread microglial activation in an Alzheimer’s patient despite treatment with lecanemab, supporting the trial rationale to target residual neuroinflammation.

#TLSA Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial

www.stocktitan.net/news/TLSA/tiziana-life-s...

StockTitan

@stocktitan.net

3 months ago

Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company Tiziana Life Sciences (Nasdaq: TLSA) intends to spin out its fully human anti-IL-6 receptor program TZLS-501 into a separately listed, immunology-focused company and will distribute shares in specie to Tiziana shareholders at a record date to be announced. TZLS-501 targets both membrane-bound and soluble IL-6R and was advanced for development due to heightened industry interest in IL-6 therapeutics, noted alongside Novartis' $1.4 billion acquisition of Tourmaline Bio.The transaction requires shareholder approval and meeting listing criteria; TZLS-501 remains a Tiziana asset until approvals are obtained.

#TLSA Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company

www.stocktitan.net/news/TLSA/tiziana-life-s...

StockTitan

@stocktitan.net

3 months ago

Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program Tiziana Life Sciences (Nasdaq: TLSA) announced on November 25, 2025 that its Phase 2 trial of intranasal foralumab in amyotrophic lateral sclerosis (ALS) was accepted into the Healey ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS at Mass General Brigham.The study, supported by a competitive grant from the ALS Association, will be led by Principal Investigators Suma Babu and James Berry and will enroll at multiple rapid-enrolling U.S. centers within the NEALS consortium. Successful investigational agents in MyMatch may advance to the HEALEY ALS Platform Trial or to standalone Phase 3 trials. The trial will use nasal immunology, blood and spinal fluid markers, cellular assays, and advanced brain imaging to evaluate foralumab’s effect on regulatory T cells and CNS inflammation.

#TLSA Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program

www.stocktitan.net/news/TLSA/tiziana-life-s...

StockTitan

@stocktitan.net

5 months ago

$1.4B Novartis Deal Sparks Tiziana's Advanced Push of Dual-Action IL-6R Antibody for Inflammatory Disease Tiziana advances TZLS-501, a dual-action IL-6R antibody, following Novartis' $1.4B Tourmaline acquisition. Drug targets both membrane-bound and soluble IL-6R for inflammatory conditions.

#TLSA Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody

www.stocktitan.net/news/TLSA/tiziana-to-adv...

StockTitan

@stocktitan.net

6 months ago

300,000 Americans with SCI: Tiziana Life Sciences Gets DoD Backing for Revolutionary Nasal Therapy DoD funds Tiziana's intranasal anti-CD3 therapy study for 17,000 annual spinal cord injuries. Three-year acute phase and two-year chronic phase research targets unmet medical need.

#TLSA Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury

www.stocktitan.net/news/TLSA/department-of-...

StockTitan

@stocktitan.net

6 months ago

36% Ownership Stake: Tiziana Life Sciences Chairman Shows Confidence With New Share Purchase Biotech firm Tiziana's Chairman Gabriele Cerrone acquires 25,000 shares at $1.60 each, increasing total holdings to 43.3M shares. Company develops intranasal foralumab immunotherapy.

#TLSA Tiziana Life Sciences Announces Purchase of Shares by Chairman

www.stocktitan.net/news/TLSA/tiziana-life-s...

StockTitan

@stocktitan.net

7 months ago

Novel Intranasal Treatment Begins Trial for Incurable Brain Disorder Affecting 50,000 Americans First patient receives innovative intranasal therapy for Multiple System Atrophy at Brigham and Women's Hospital. Novel approach targets neuroinflammation in rare brain disease. Learn more.

#TLSA Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

www.stocktitan.net/news/TLSA/tiziana-life-s...

StockTitan

@stocktitan.net

7 months ago

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy Tiziana Life Sciences (NASDAQ:TLSA) has received FDA approval for its Phase 2a Investigational New Drug (IND) application to study intranasal foralumab in Multiple System Atrophy (MSA) patients. The six-month, open-label clinical trial will evaluate foralumab, a fully human anti-CD3 monoclonal antibody, for its effects on microglial activation, clinical outcomes, and safety.MSA is a rare, rapidly progressive neurodegenerative disorder with no FDA-approved treatments. The disease affects 1.9-4.9 per 100,000 people worldwide, with a median survival of 6-9 years. The trial (NCT06868628) will administer foralumab via nasal spray in eight 3-week dosing cycles, targeting T-cell mediated neuroinflammation.

#TLSA FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

www.stocktitan.net/news/TLSA/fda-approves-t...

Dr. Business, MBA

@dr-business.bsky.social

7 months ago

BREAKING - Tesla cars are breaking. I hate you Hayden, you have financial destroyed our network and now we are all unpaid interns now.

#Tech #finance #analyst #MBA #TLSA

StockTitan

@stocktitan.net

7 months ago

Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient Tiziana Life Sciences (NASDAQ:TLSA) has reported promising immunologic findings from treating a moderate Alzheimer's Disease patient with intranasal foralumab, their lead immunomodulation therapy. The analysis revealed significant immune modulatory effects in white blood cells, including changes in CD4 cells, CD8 cells, and monocytes.Key findings include a marked reduction in brain inflammation confirmed by microglia PET scans and an unexpected increase in phagocytosis markers in classical monocytes, suggesting potential for enhanced amyloid plaque clearance. The treatment was well-tolerated with no side effects, and the patient will continue therapy for an additional 6 months.

#TLSA Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient

www.stocktitan.net/news/TLSA/tiziana-life-s...

Wall Street Game Notes

@wallstgamenotes.bsky.social

8 months ago

From Skeptic to Bull: I’m Finally In on #Uber + The Upside of the “Autonomous Driving Boom” YouTube video by Wall Street Game Notes

From Skeptic to Bull: I’m Finally In on #Uber + The Widespread Upside of the “Autonomous Driving Boom”

#MU #NKE #TLSA #NVDA #LYFT #GOOG #GOOGL #Waymo #AutonomousDriving #SelfDrivingCars #AIStocks #TechStocks #Investing #StockMarket #FutureOfTransport #WallStreetGameNotes

youtu.be/e-28tsv9nCA

PRISM MarketView

@prismmarketview.bsky.social

9 months ago

3D rendering of monoclonal antibodies in vibrant blue and orange colors, representing advanced immunotherapy research by Tiziana Life Sciences.

#TLSA is up 12% as Tiziana expands its Phase 2 trial of intranasal foralumab for progressive MS to Weill Cornell. A novel nasal therapy targeting immune tolerance could offer new hope for patients with limited options.
#TizianaLifeSciences
prismmarketview.com/tiziana-rise...

StockTitan

@stocktitan.net

9 months ago

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center Tiziana Life Sciences (NASDAQ: TLSA) has expanded its Phase 2 clinical trial of intranasal foralumab by initiating patient dosing at Weill Cornell Multiple Sclerosis Center, marking the fifth site in their study. The trial evaluates foralumab, a first-in-class fully human anti-CD3 monoclonal antibody, in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This site joins existing locations at Yale University, Johns Hopkins University, Brigham and Women's Hospital, and the University of Massachusetts. The study includes a six-month open-label extension phase following the blinded phase, allowing all participants to receive foralumab. The treatment's innovative intranasal delivery method aims to engage regulatory T cells and promote immune tolerance while minimizing systemic immune suppression.

#TLSA Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

www.stocktitan.net/news/TLSA/tiziana-life-s...

@kingbradentucky.bsky.social

9 months ago

#TLSA days high on cars that cannot sell and robotaxis that won't work.

Efficient markets indeed!

StockTitan

@stocktitan.net

10 months ago

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease Tiziana Life Sciences (NASDAQ: TLSA) has published promising results in the Journal of Clinical Nuclear Medicine regarding their intranasal foralumab treatment for Alzheimer's Disease (AD). The study, conducted at Brigham and Women's Hospital, demonstrated significant reduction in microglial activation in a 78-year-old patient with moderate AD. Using advanced PET imaging with [F-18]PBR06 tracer, researchers observed notable decrease in neuroinflammation after treatment. Foralumab, the only fully human anti-CD3 monoclonal antibody for intranasal delivery, works by modulating T cell function to reduce central nervous system inflammation. The company is now initiating a phase-2a study of nasal-foralumab in mild Alzheimer's, targeting an area with no currently approved disease-modifying therapies.

#TLSA Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

www.stocktitan.net/news/TLSA/journal-of-cli...

StockTitan

@stocktitan.net

10 months ago

Tiziana Life Sciences Announces Purchase of Shares by Chairman Tiziana Life Sciences (NASDAQ: TLSA) announced that Executive Chairman and Founder Gabriele Cerrone has increased his stake in the company through the purchase of 15,000 common shares at $1.55 per share. Following this transaction, Cerrone's total holdings have reached 43,252,143 common shares, representing 37.02% of the company's issued share capital. Tiziana is developing immunomodulation therapies, with its lead candidate being intranasal foralumab, a fully human anti-CD3 monoclonal antibody.

#TLSA Tiziana Life Sciences Announces Purchase of Shares by Chairman

www.stocktitan.net/news/TLSA/tiziana-life-s...

StockTitan

@stocktitan.net

10 months ago

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab Tiziana Life Sciences (NASDAQ: TLSA) reported promising results from a PET scan showing significant reduction in microglia activation in a moderate Alzheimer's disease patient treated with intranasal foralumab for three months under an expanded access program. The scan revealed decreased neuroinflammation, a key factor in Alzheimer's progression. Dr. Howard Weiner presented these findings at the 2025 AD/PD Conference in Vienna. The treatment showed no side effects, and the patient continues receiving foralumab. This breakthrough is particularly significant as no approved therapies currently exist for moderate Alzheimer's. Foralumab, a fully human anti-CD3 monoclonal antibody, works by inducing Tregs that travel to the brain to reduce neuroinflammation. The treatment shows potential both as a standalone therapy and in combination with existing amyloid-targeting treatments.

#TLSA Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

www.stocktitan.net/news/TLSA/tiziana-life-s...

StockTitan

@stocktitan.net

10 months ago

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis Tiziana Life Sciences (NASDAQ: TLSA) has announced positive results from a clinical study of nasal foralumab in treating non-active secondary progressive multiple sclerosis (na-SPMS). The study involved 10 patients who were treated for a minimum of six months, with key findings including: - No serious treatment-related adverse events reported - Stabilization of Expanded Disability Status Scale (EDSS) scores in all patients - Improvement in fatigue symptoms in 6 out of 10 patients - Significant reductions in microglial activation at six months (p - No new T2 lesions observed on MRI - Increased regulatory T cells and TGFβ expression The company has initiated a randomized, double-blind, placebo-controlled Phase 2 clinical trial with expected top-line data by the end of 2025. The treatment represents a novel approach for na-SPMS patients who currently have limited treatment options.

#TLSA Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

www.stocktitan.net/news/TLSA/tiziana-life-s...

StockTitan

@stocktitan.net

10 months ago

Breakthrough MS Treatment Trial: UMass Joins Harvard, Yale, Johns Hopkins Testing Home-Use Nasal Drug First-ever intranasal antibody for MS enters testing at UMass, joining three elite medical centers. Revolutionary at-home treatment could transform MS care. See trial details.

#TLSA Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

www.stocktitan.net/news/TLSA/tiziana-life-s...